Cargando…
Evaluation of KRAS(G12C) inhibitor responses in novel murine KRAS(G12C) lung cancer cell line models
INTRODUCTION: The KRAS(G12C) mutation is the most common genetic mutation in North American lung adenocarcinoma patients. Recently, direct inhibitors of the KRAS(G12C) protein have been developed and demonstrate clinical response rates of 37-43%. Importantly, these agents fail to generate durable th...
| Autores principales: | , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Frontiers Media S.A.
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9945252/ https://www.ncbi.nlm.nih.gov/pubmed/36845684 http://dx.doi.org/10.3389/fonc.2023.1094123 |